• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring

    5/29/25 6:55:00 AM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KROS alert in real time by email

    Discontinues Development of Cibotercept in PAH

    Announces Corporate Restructuring to Align Operations with Ongoing Strategic Priorities

    LEXINGTON, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros", the "Company" or "we") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced topline data from the TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension ("PAH"), and provided a corporate update.

    TROPOS Trial Results

    TROPOS is a randomized, double-blind, placebo-controlled, global Phase 2 clinical trial to evaluate cibotercept in combination with background therapy in patients with PAH. On December 12, 2024, the Company announced that it had voluntarily halted the 3.0 mg/kg and 4.5 mg/kg treatment arms based on the observation of pericardial effusions at those dose levels. Furthermore, on January 15, 2025, the Company announced that it had voluntarily halted all dosing in the trial, including the 1.5 mg/kg and placebo treatment arms, based on the ongoing safety review due to new observations of pericardial effusion adverse events. Following the early termination of the trial, patients continued to be monitored through their end-of-trial visits.

    Following the analysis of all available safety and efficacy data from the TROPOS trial, the Company has decided to discontinue all development of cibotercept in PAH.

    "Additional treatment options for individuals with PAH are critically needed," said Jasbir S. Seehra, Ph.D, Chair and Chief Executive Officer. "We are immensely grateful to the patients, investigators and Keros colleagues for their dedication to seeking new treatment options for this devastating disease."

    The Company shared top-line results in a presentation that will be accessible in the Investors section of the Keros website at https://ir.kerostx.com. The Company plans to submit more detailed findings from the TROPOS trial at a future medical meeting.

    The Company plans to further evaluate the appropriate development strategy for cibotercept, if any, in other indications following the completion of the strategic alternative review process.

    Corporate Restructuring

    In connection with the decision to discontinue all development of cibotercept in PAH and an assessment of its ongoing development programs, the Keros Board of Directors (the "Board") and management team have decided to reduce the Company's headcount by approximately 45%, after which the Company will have 85 full-time employees. The reduction in headcount will commence after the 60-day notice period required by the Worker Adjustment and Retraining Notification Act has elapsed, and as a result of these actions, Keros expects to realize average annualized cost savings of approximately $17 million.

    Dr. Seehra added, "Consistent with our commitment to being data driven and taking action to best position Keros to drive sustainable stockholder value, we have identified opportunities to restructure our operations and reduce costs as we focus on our key ongoing development programs. As a result, we have made the difficult decision to reduce our workforce to better align with our strategic priorities. We appreciate the hard work and dedication of our impacted team members and we are committed to supporting them through this transition. Looking ahead, Keros maintains a robust balance sheet and we are making meaningful progress on our other development programs. Our focus remains on the execution of our strategy as we concurrently work to complete the ongoing review of strategic alternatives to maximize value for all stockholders."

    As previously announced on April 10, 2025, with the assistance of outside financial and legal advisors, the Strategic Committee of the Board, which consists of independent and disinterested directors, is continuing to evaluate a comprehensive range of strategic alternatives, including but not limited to a sale of the Company or other business combination transaction, continued investment in the Company's pipeline, and/or return of excess capital to stockholders. Keros intends to provide a preliminary update regarding the status of the process no later than June 9, 2025.

    About TROPOS (NCT05975905)

    TROPOS is a randomized, double-blind, placebo-controlled, global Phase 2 clinical trial to evaluate cibotercept in combination with background therapy in patients with PAH. The primary objective of this trial is to evaluate the effect of cibotercept on pulmonary hemodynamics compared to placebo in participants on background PAH therapy. The key secondary objective of this trial is to evaluate the effect of cibotercept on exercise capacity compared to placebo on participants on background PAH therapy.

    About Keros Therapeutics, Inc.



    Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-ß family of proteins. Keros is a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including blood, bone, skeletal muscle, adipose and heart tissue. By leveraging this understanding, Keros has discovered and is developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients. Keros' lead product candidate, KER-065, is being developed for the treatment of neuromuscular diseases, with an initial focus on Duchenne muscular dystrophy. Keros' most advanced product candidate, elritercept (KER-050), is being developed for the treatment of cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and in patients with myelofibrosis.

    Cautionary Note Regarding Forward-Looking Statements

    Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "anticipates," "believes," "continue," "expects," "enable," "potential" and "will" or similar expressions are intended to identify forward-looking statements. Examples of these forward-looking statements include statements concerning the intended benefits and outcome of the strategic review process (including timing of announcing an update), expected development and regulatory pathway and therapeutic benefits of cibotercept and the Company's other product candidates, any anticipated benefits of the reduction in force (including anticipated cost savings), and the Company's cash runway. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: whether the objectives of the strategic alternative review process will be achieved; the terms, structure, benefits and costs of any strategic transaction; the timing of any transaction and whether any transaction will be consummated at all; the risk that the strategic alternatives review, workforce reduction and the announcements thereof could have an adverse effect on the ability of the Company to retain and hire key personnel and maintain relationships with partners, suppliers, employees, stockholders and other business relationships and on its operating results and business generally; the risk the strategic alternatives review could divert the attention and time of the Company's management; the risk of any unexpected costs or expenses resulting from the review; the risk of any litigation relating to the review; Keros' limited operating history and historical losses; Keros' ability to raise additional funding to complete the development and any commercialization of its product candidates; Keros' dependence on the success of its product candidates, KER-065 and elritercept; that Keros may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses; the risk that circumstances surrounding or leading up to our 2025 Annual Meeting may change; Keros' ability to obtain, maintain and protect its intellectual property; Keros' dependence on third parties in connection with manufacturing, clinical trials and preclinical studies; the impact of the workforce reduction, including any unexpected costs, expenses, or litigation.

    These and other risks are described more fully in Keros' filings with the Securities and Exchange Commission (the "SEC"), including the "Risk Factors" section of the Company's Quarterly Report on Form 10-Q, filed with the SEC on May 6, 2025, and its other documents subsequently filed with or furnished to the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, Keros undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

    Contacts

    Investor Contact:

    Justin Frantz

    [email protected]

    617-221-6042

    Media Contact:

    Mahmoud Siddig / Adam Pollack / Viveca Tress

    Joele Frank, Wilkinson Brimmer Katcher

    (212) 355-4449



    Primary Logo

    Get the next $KROS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KROS

    DatePrice TargetRatingAnalyst
    1/21/2025Overweight → Neutral
    Cantor Fitzgerald
    1/17/2025$15.00Outperform → Neutral
    Wedbush
    12/16/2024$102.00 → $63.00Outperform
    Oppenheimer
    12/16/2024Buy → Neutral
    Guggenheim
    12/13/2024$100.00 → $47.00Buy
    H.C. Wainwright
    12/12/2024Buy → Hold
    TD Cowen
    12/12/2024Outperform → Mkt Perform
    William Blair
    12/12/2024Buy → Neutral
    BTIG Research
    More analyst ratings

    $KROS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Adar1 Capital Management, Llc bought $328,127 worth of shares (34,925 units at $9.40) (SEC Form 4)

      4 - Keros Therapeutics, Inc. (0001664710) (Issuer)

      4/11/25 9:57:19 PM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Adar1 Capital Management, Llc claimed ownership of 4,456,706 shares (SEC Form 3)

      3 - Keros Therapeutics, Inc. (0001664710) (Issuer)

      4/11/25 8:58:32 PM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF EXECUTIVE OFFICER Seehra Jasbir exercised 49,367 shares at a strike of $0.30, increasing direct ownership by 20% to 302,223 units (SEC Form 4)

      4 - Keros Therapeutics, Inc. (0001664710) (Issuer)

      4/7/25 4:15:07 PM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KROS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Adar1 Capital Management, Llc bought $328,127 worth of shares (34,925 units at $9.40) (SEC Form 4)

      4 - Keros Therapeutics, Inc. (0001664710) (Issuer)

      4/11/25 9:57:19 PM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KROS
    Financials

    Live finance-specific insights

    See more

    $KROS
    SEC Filings

    See more

    $KROS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $KROS
    Leadership Updates

    Live Leadership Updates

    See more

    $KROS
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $KROS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Keros Therapeutics Reports Recent First Quarter 2025 Financial Results

      LEXINGTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today reported financial results for the quarter ended March 31, 2025. "In the first quarter, we reported initial topline results from the Phase 1 clinical trial of KER-065 that met key objectives and yielded valuable insights. These findings position us well as we prepare to engage with regulators with the aim

      5/6/25 4:01:42 PM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Keros Therapeutics Announces Review of Strategic Alternatives

      Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process LEXINGTON, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that its Board of Directors (the "Board") has determined to initiate a formal review process to evaluate strategic alternatives to maximize stockholder value for the Company. In connection with this determination, th

      4/10/25 6:00:00 AM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers

      Trial achieved key objectives for safety, tolerability, pharmacokinetics and pharmacodynamicsClinical data from this trial, together with preclinical data, support the therapeutic potential of KER-065 for broad impact in Duchenne muscular dystrophy ("DMD") and other neuromuscular indicationsKeros plans on advancing KER-065 into a Phase 2 clinical trial in DMD, subject to positive regulatory interactionKeros to host a conference call and webcast today, March 31, 2025, at 8:00 a.m. ET LEXINGTON, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutic

      3/31/25 6:00:00 AM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Keros Therapeutics Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Other Events, Financial Statements and Exhibits

      8-K - Keros Therapeutics, Inc. (0001664710) (Filer)

      5/29/25 6:58:59 AM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Keros Therapeutics Inc.

      DEFA14A - Keros Therapeutics, Inc. (0001664710) (Filer)

      5/27/25 1:49:00 PM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Keros Therapeutics Inc.

      DEFA14A - Keros Therapeutics, Inc. (0001664710) (Filer)

      5/19/25 8:02:47 AM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Keros Therapeutics downgraded by Cantor Fitzgerald

      Cantor Fitzgerald downgraded Keros Therapeutics from Overweight to Neutral

      1/21/25 7:51:46 AM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Keros Therapeutics downgraded by Wedbush with a new price target

      Wedbush downgraded Keros Therapeutics from Outperform to Neutral and set a new price target of $15.00

      1/17/25 11:09:49 AM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer reiterated coverage on Keros Therapeutics with a new price target

      Oppenheimer reiterated coverage of Keros Therapeutics with a rating of Outperform and set a new price target of $63.00 from $102.00 previously

      12/16/24 8:15:23 AM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Keros Therapeutics Appoints Yung H. Chyung, M.D., as Chief Medical Officer

      LEXINGTON, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced the appointment of Yung H. Chyung, M.D., as Keros' Chief Medical Officer, effective as of November 1, 2024. "We are thrilled to welcome Yung to Keros and look forward to leveraging his development and TGF-ß superfamily expertise as we continue to advance our clinical programs," said Chair and Chi

      10/16/24 8:00:00 AM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Keros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of Directors

      LEXINGTON, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that it appointed Jean-Jacques Bienaimé to its Board of Directors, effective June 1, 2024. "On behalf of the Board, we are delighted to welcome Jean-Jacques to Keros during this pivotal phase of our growth," said President and Chief Executive Officer Jasbir Seehra, Ph.D. "Jean-Jacques is a deeply

      5/28/24 4:01:00 PM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Keros Therapeutics Appoints Alpna Seth, Ph.D., to its Board of Directors

      LEXINGTON, Mass., April 19, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, today announced that it appointed Alpna Seth, Ph.D., to its Board of Directors, effective May 1, 2023. "Dr. Seth's deep industry experience and expertise in drug development, global operations and product launches will be an invaluable addition to our Board of Directors," said President and Chief Executive Officer Jasbir Seehra, Ph.D. "We a

      4/19/23 8:00:00 AM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring

      Discontinues Development of Cibotercept in PAH Announces Corporate Restructuring to Align Operations with Ongoing Strategic Priorities LEXINGTON, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros", the "Company" or "we") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced topline data from the TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arte

      5/29/25 6:55:00 AM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote "FOR" All of Keros' Director Nominees

      Keros Board Best Equipped to Oversee Strategic Review Process and Execute on Ultimate Outcome of that Process ADAR1's Disruptive and Self-Serving Campaign Stands to Jeopardize the Future Value Maximizing Potential of the Company Keros Urges Stockholders to Protect the Value of Their Investment by Voting "FOR" All Three of the Company's Highly Qualified Director Nominees LEXINGTON, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros", the "Company" or "we") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling o

      5/27/25 1:45:00 PM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ADAR1 Announces ISS Recommends Keros Therapeutics Stockholders WITHHOLD Votes from Directors Dr. Mary Ann Gray and Dr. Alpna Seth

      ADAR1 Urges Board to Release Strategic Review Results Before, Not After, Annual Meeting AUSTIN, Texas, May 21, 2025 /PRNewswire/ -- ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1" or "We"), the largest stockholder of Keros Therapeutics (NASDAQ:KROS) ("Keros" or the "Company") with approximately 13.3% of the Company's outstanding shares, today announced that leading independent proxy advisory firm Institutional Shareholder Services Inc. ("ISS") has recommended that Keros stockholders WITHHOLD votes from incumbent directors Dr. Mary Ann Gray and Dr. Alpna Seth at the Company's upcoming Annual Meeting of Stockholders (the "Annual Meeting"), scheduled for June 4, 2025.

      5/21/25 8:00:00 AM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Keros Therapeutics Inc. (Amendment)

      SC 13G/A - Keros Therapeutics, Inc. (0001664710) (Subject)

      2/13/24 6:38:35 PM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Keros Therapeutics Inc. (Amendment)

      SC 13G/A - Keros Therapeutics, Inc. (0001664710) (Subject)

      2/9/24 9:16:07 AM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Keros Therapeutics Inc. (Amendment)

      SC 13G/A - Keros Therapeutics, Inc. (0001664710) (Subject)

      1/26/24 5:26:51 PM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care